Reuters Market Eye - Shares of Indoco Remedies Ltd surge 14.2 percent after the company said on Monday that the U.S. drug regulator had approved the company's sterile and solid dosage manufacturing plants located in Goa, paving the way for its ophthalmic product launches in the United States.
This is a significant positive for the company as the sale of products from these plants should contribute 30 percent of Indoco's FY16 operating profit, brokerage Religare said in a report on Monday.
"We expect the stock's discounted multiples (vs. peers) to narrow on strong EPS growth (45% CAGR over FY14-FY17E) and improving return ratios," the note said.
(Reporting by Abhishek Vishnoi)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app